LoadingLoadingLoadingThe quick read
Latest quote·Oct 14
No insider open-market trades in 90 days (SEC Form 4). Congress: no trades disclosed in 180 days.
Analyst target and ratings are on paid plans
See the 12-month consensus target and the buy/hold/sell rating split.
Unlock the full resultsNeither. Protalix Biotherapeutics Inc (PLX) insiders filed no open-market purchases or sales in the 90 days to Oct 16, 2026, according to SEC Form 4 filings.
None. No member of Congress disclosed a PLX trade with a trade date in the last 180 days, according to House and Senate STOCK Act filings.
This summary uses filings available on Oct 16, 2026. Insiders must report trades to the SEC within 2 business days, members of Congress have up to 45 days to disclose a trade, and funds file 13F holdings up to 45 days after each quarter ends, so the latest moves may not be public yet.
8 funds hold a position.
No tracked top-trader positions in PLX right now.
Live Hyperliquid positioning - not every stock is covered
Last report
Aug 12, 2026
Period ending
Jun 30, 2026
Earnings per share
-$0.01 expected
Revenue
No reported revenue on record
| Period ending | Reported | EPS / estimate | EPS surprise | Revenue / estimate | Rev. surprise |
|---|---|---|---|---|---|
| Jun 30, 2026 | Aug 12, 2026 | $0.05 / -$0.01Alpha Vantage | +$0.06 beat | Unavailable | Unavailable |
| Mar 31, 2026 | May 13, 2026 | $0.22 / -$0.01Alpha Vantage | +$0.23 beat | Unavailable | Unavailable |
| Dec 31, 2025 | Mar 18, 2026 | -$0.07 / $0.04Alpha Vantage | -$0.11 miss | Unavailable | Unavailable |
| Sep 30, 2025 | Nov 13, 2025 | $0.03 / $0.06Alpha Vantage | -$0.03 miss | Unavailable | Unavailable |
| Jun 30, 2025 | Aug 14, 2025 | -$0.04 / $0.03Alpha Vantage | -$0.07 miss | Unavailable | Unavailable |
| Mar 31, 2025 | May 9, 2025 | -$0.05 / $0.08Alpha Vantage | -$0.13 miss | Unavailable | Unavailable |
| Dec 31, 2024 | Mar 17, 2025 | $0.09 / $0.07Alpha Vantage | +$0.02 beat | Unavailable | Unavailable |
| Sep 30, 2024 | Nov 14, 2024 | $0.03 / $0.06Alpha Vantage | -$0.03 miss | Unavailable | Unavailable |
EPS uses Yahoo Finance where available, then Alpha Vantage or verified release comparisons. Revenue uses company releases and saved estimates.
| USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| What came in | ||||
| Revenue | $17.9M | $9.1M | $33.8M | $19.9M |
| Cost of what it sold | $8.3M | $4.6M | $4.1M | $7.8M |
| Gross profit | $9.5M | $4.5M | $29.6M | $12.1M |
| What it spent | ||||
| Research and development | $4.5M | $5.6M | $5.4M | $4.4M |
| Sales and admin | $2.9M | $3.5M | $4.4M | $3.1M |
| Other operating costs | — | — | -$1.3M | — |
| Total operating expenses | $7.4M | $9.2M | $8.5M | $7.5M |
| What was left | ||||
| Operating profit | $2.1M | -$4.7M | $21.1M | $4.7M |
| Interest on debt | $180.0K | $383.0K | $193.0K | $494.0K |
| Profit before tax | $2.2M | -$4.8M | $21.1M | $4.9M |
| Tax | -$116.0K | $728.0K | $2.8M | $1.1M |
| Net profit | $2.4M | -$5.5M | $18.3M | $3.8M |
| EBITDA | $2.8M | -$4.0M | $21.7M | $5.8M |
This stock's price action is mixed.
Trend
Mixed
45 / 100
RSI 14
20D volatility
52-week range
20D support
20D resistance
Returns
Price vs moving averages
Volume pace
